TNF-α blockers such as infliximab are associated with reactivation of TB based on data from postmarketing surveillance reports.3 According to this report, 70 patients developed TB after a median time period of 12 weeks after starting infliximab, with the majority developing extrapulmonary TB.3 Of note, the screening for latent TB prior to initiation of infliximab therapy was not mandatory at that time. The gene discussed is TNF; the disease is tuberculosis.